Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Letrozole vs FEC in ER+/HER2- Breast Cancer
NCT02742051Phase 2Completed
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jun 2016
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of everolimus in breast cancer (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Feasibility of the trial at 18 weeks. Started Jun 2016; status: completed.
02
Drugs
everolimus
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02742051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02742051.